Oliver Sum-Ping, MD
Sleep Medicine · Stanford, CANPI 1972894129
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,093 of the $24,497 with a category attached, or 73.9%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 98.4% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $17,128, 5.0 times the $3,426 reported in 2023. Among sleep medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $628.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- Jazz Pharmaceuticals Inc.$349
- Avadel CNS Pharmaceuticals, LLC$39
Across 1 payment — averaging $58.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$58
What the payments were for
- Consulting fees$18,09374%
- Travel & lodging$5,33222%
- Food & beverage$1,0724%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $24,109 |
| Jazz Pharmaceuticals Inc. | 5 | $349 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $39 |
How this compares
$24,497 in reported general payments places this provider in the 90th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zolpidem Tartrate | 27 | $984 |
| Gabapentin | 25 | $877 |
| Methadone Hcl | 36 | $337 |
| Clonazepam | 16 | $302 |
| Armodafinil | 12 | $264 |
| Pregabalin | 11 | $146 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in Stanford
- Logan SchneiderStanford$506K
- Emmanuel MignotStanford$135K
- Clete KushidaStanford$58K
- Scott KutscherStanford$36K
- Julianna RodinStanford$18K
- Rafael PelayoStanford$15K
- Robson CapassoStanford$6K
- Pedro Gomes de OliveiraStanford$4K
- Lisa ShivesSan Diego$1.4M
- Haramandeep SinghSan Ramon$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.